Nimotuzumab, CAS 780758-10-3

Product Description: Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC)[1][2].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382./[2]Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1(1):41-8.

CAS Number: 780758-10-3

Molecular Weight: N/A

Compound Purity: 96.70

Research Area: Cancer

Solubility: H2O

Target: EGFR

• Artikelnummer: MEXHY-P9968-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9968-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated